Generic competition · all medicines · read 12 November 2026
Is there a generic of Amlodipine Besylate, and who makes it?
Amlodipine Besylate appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 13.2 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Amlodipine Besylate appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them.
- 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came 13.2 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Brand listed as marketed: Norvasc. 18 generic makers with 57 generic products listed as marketed; the first generic approval is dated 3 October 2005.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Macleods Pharmaceuticals Ltd | 23 May 2007 | 3 |
| Teva Pharmaceuticals Usa Inc | 28 June 2007 | 3 |
| Zydus Pharmaceuticals Usa Inc | 9 July 2007 | 3 |
| Lupin Ltd | 12 July 2007 | 3 |
| Aurobindo Pharma Ltd | 17 July 2007 | 3 |
| Chartwell Rx Sciences Llc | 20 July 2007 | 3 |
| Invagen Pharmaceuticals Inc | 28 August 2007 | 6 |
| Cipla Ltd | 26 September 2007 | 3 |
| Epic Pharma Llc | 8 April 2009 | 3 |
| Alkem Laboratories Ltd | 4 May 2009 | 3 |
| Orbion Pharmaceuticals Private Ltd | 2 July 2009 | 3 |
| Oxford Pharmaceuticals Llc | 7 April 2010 | 3 |
6 more makers are listed in the data.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
For Solution, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Sdamlo. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Tablet, Orally Disintegrating, Oral
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Norliqva. No generic is listed as marketed.
Patents and exclusivities still listed
- 24 February 2041Patent 12226528 drug product
- 24 February 2041Patent 11458095 drug product
- 24 February 2041Patent 12005141 drug product
- 24 February 2041Patent 12440441 drug product
- 24 February 2041Patent 11723866 drug product
- 24 February 2041Patent 11253474 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.